FDA Approves Alvotech's Process 2.0, More Than Doubling SIMLANDI Output Per Batch

summarizeSummary

The FDA approved Alvotech's Process 2.0 for SIMLANDI manufacturing, more than doubling drug substance output per batch and freeing capacity for the rest of its biosimilar portfolio.

check_boxKey Events · Product Development and Regulatory · ALVO

• FDA Approves SIMLANDI Process 2.0

  The FDA approved a new manufacturing process for adalimumab drug substance in Alvotech's DSM2 suite in Reykjavik, with demonstrated comparability to the previously approved process.

• Output Per Batch More Than Doubles

  The new process more than doubles drug substance output per batch without changing the upstream manufacturing scale, so the same quantity is made in fewer batches.

• Capacity Freed for Portfolio

  Freed DSM2 capacity can support other products in Alvotech's biosimilar portfolio and add flexibility to meet growing demand, per COO Joseph McClellan.

• Builds on Recent Manufacturing Approvals

  Follows the July 2026 FDA close-out of the Reykjavik facility inspection and the October 5, 2026 approval of a second drug-substance production site.

auto_awesomeAnalysis · ALVO · Life Sciences

The FDA has cleared a new manufacturing process for SIMLANDI that more than doubles drug substance output per batch without adding upstream scale. The same volume of adalimumab can therefore be made in fewer batches, freeing DSM2 capacity in Reykjavik for other products in the portfolio and giving Alvotech more room to meet demand. This follows the July 2026 close-out of the FDA's facility inspection and the October 5 approval of a second drug-substance production site, so the manufacturing base behind the biosimilar portfolio keeps widening. No financial terms or capacity figures in units were disclosed, so the earnings effect is not quantified here.